Results 1 to 10 of about 309,486 (308)

Improved Specificity and Safety of Anti-Hepatitis B Virus TALENs Using Obligate Heterodimeric FokI Nuclease Domains

Viruses, 2021
Persistent hepatitis B virus (HBV) infection remains a serious medical problem worldwide, with an estimated global burden of 257 million carriers. Prophylactic and therapeutic interventions, in the form of a vaccine, immunomodulators, and nucleotide and ...
Tiffany Smith, Prashika Singh, Kay Ole Chmielewski, Kristie Bloom, Toni Cathomen, Patrick Arbuthnot, Abdullah Ely   +6 more
doaj   +1 more source

HCV Genotype Distribution and Clinical Characteristics of HCV Mono-Infected and HCV/HIV Co-Infected Patients in Liangshan Prefecture, Sichuan Province, China

Journal of the International Association of Providers of AIDS Care, 2023
Objective: The present study aimed to characterize the genotype distribution and clinical characteristics of HCV monoinfected and HCV/HIV coinfected patients in the Liangshan Prefecture, Sichuan Province, China.
Bianchuan Cao PhD, Mei Liu BD, Tao Jiang BD, Qinghua Yu BD, Tianru Yuan BD, Ping Ding BD, Xian Zhou BD, Yongmao Huang MD, Yongsheng Zou BD, Fuli Huang PhD   +9 more
doaj   +1 more source

Advances in designing Adeno-associated viral vectors for development of anti-HBV gene therapeutics

Virology Journal, 2021
Despite the five decades having passed since discovery of the hepatitis B virus (HBV), together with development of an effective anti-HBV vaccine, infection with the virus remains a serious public health problem and results in nearly 900,000 annual ...
Njabulo Mnyandu, Shonisani Wendy Limani, Patrick Arbuthnot, Mohube Betty Maepa   +3 more
doaj   +1 more source

Production, Characterization, and Assessment of Permanently Cationic and Ionizable Lipid Nanoparticles for Use in the Delivery of Self-Amplifying RNA Vaccines

Pharmaceutics, 2023
Africa bears the highest burden of infectious diseases, yet the continent is heavily reliant on First World countries for the development and supply of life-saving vaccines.
Dylan Kairuz, Nazia Samudh, Abdullah Ely, Patrick Arbuthnot, Kristie Bloom   +4 more
doaj   +1 more source

Cyclodextrins in the antiviral therapy

Journal of Drug Delivery Science and Technology, 2021
The main antiviral drug-cyclodextrin interactions, changes in physicochemical and physiological properties of the most commonly used virucides are summarized. The potential complexation of antiviral molecules against the SARS-Cov2 also pointed out the lack of detailed information in designing effective and general medicines against viral infections ...
Jicsinszky L., Martina K., Cravotto G.
openaire   +2 more sources

Advances with RNAi-Based Therapy for Hepatitis B Virus Infection

Viruses, 2020
Infection with hepatitis B virus (HBV) remains a global health challenge. Approximately 292 million people worldwide are chronically infected with HBV and the annual mortality from the infection is approaching 900,000.
Fiona van den Berg, Shonisani Wendy Limani, Njabulo Mnyandu, Mohube Betty Maepa, Abdullah Ely, Patrick Arbuthnot   +5 more
doaj   +1 more source

AAV Immunotoxicity: Implications in Anti-HBV Gene Therapy

Microorganisms, 2023
Hepatitis B virus (HBV) has afflicted humankind for decades and there is still no treatment that can clear the infection. The development of recombinant adeno-associated virus (rAAV)-based gene therapy for HBV infection has become important in recent ...
Ridhwaanah Jacobs, Makafui Dennis Dogbey, Njabulo Mnyandu, Keila Neves, Stefan Barth, Patrick Arbuthnot, Mohube Betty Maepa   +6 more
doaj   +1 more source

A Phase 1 randomized study of GSK3732394, an investigational long-acting biologic treatment regimen for HIV-1 infection

Antiviral Therapy, 2022
Background The GSK3732394 multivalent protein was developed as a novel, long-acting, antiretroviral biologic treatment regimen with three independent, non–cross-resistant mechanisms for inhibiting HIV-1 entry.
Mark Krystal, Shiven Chabria, Daren Austin, Allen Wolstenholme, David Wensel, Max Lataillade, Judah Abberbock, Mark Baker, Peter Ackerman   +8 more
doaj   +1 more source

JNJ-73763989 pharmacokinetics and safety: Liver-targeted siRNAs against hepatitis B virus, in Japanese and non-Japanese healthy adults, and combined with JNJ-56136379 and a nucleos(t)ide analogue in patients with chronic hepatitis B

Antiviral Therapy, 2022
Background JNJ-73763989 comprises two hepatitis B virus (HBV)-specific, liver-targeted N-galactosamine-conjugated short interfering RNA triggers, JNJ-73763976 and JNJ-73763924.
Ed Gane, Man-Fung Yuen, Thomas N Kakuda, Tetsuro Ogawa, Yasushi Takahashi, Nele Goeyvaerts, Isabelle Lonjon-Domanec, Tamisha Vaughan, Thomas Schluep, James Hamilton, Emmanuel Njumbe Ediage, Vera Hillewaert, Jan Snoeys, Oliver Lenz, Willem Talloen, Michael Biermer   +15 more
doaj   +1 more source

Inhibition of replication of hepatitis B virus using transcriptional repressors that target the viral DNA

BMC Infectious Diseases, 2019
Background Chronic infection with hepatitis B virus (HBV) is a serious global health problem. Persistence of the virus occurs as a result of stability of the replication intermediate comprising covalently closed circular DNA (cccDNA).
Kristie Bloom, Haajira Kaldine, Toni Cathomen, Claudio Mussolino, Abdullah Ely, Patrick Arbuthnot   +5 more
doaj   +1 more source